Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 17, 2010

View Archived Issues

First oral anaphylatoxin C5a receptor antagonist CCX-168 is safe in phase I trial

EMA orphan drug status for SBC-102 in LAL deficiency / News in Context

Preclinical studies evaluate Cz-007, Cz-008 and Cz-009 for treatment of Chagas' disease

Preclinical and first-in-human data reported on antimalarial OZ-439

ProStrakan provides update on Orexo's Abstral for cancer pain

GSK and Fiocruz expand collaboration to develop new drugs for tropical diseases

SUN-13837 accelerates functional recovery in rat models of spinal cord injury and stroke

FDA approves Vyvanse for ADHD in adolescents

Wyeth describes new PI3K-alpha/gamma and mTOR inhibitors

Isis and Xenon Pharma to develop hemojuvelin- and hepcidin-targeted drugs for anemia of inflammation

FDA grants orphan drug status to MP4CO for painful crises of sickle cell disease

Isotechnika and ILJIN to codevelop voclosporin for transplant indications

AtheroNova and Cedars-Sinai Heart Institute partner on treatment to reduce arterial plaques

Albert Einstein College of Medicine claims new Tim16 inhibitors

Infinity Pharma advances phase Ib/II IPI-926 trial in pancreatic cancer

InteRNA Technologies receives grant from Dutch government to develop miRNA-based therapeutics

Ono Pharma begins phase II trial of subcutaneous methylnaltrexone in Japan

ReNeuron treats first patient in phase I trial of ReN-001 stem cells in stroke

Lilly presents new inhibitors of 5HTT and NET

Angioblast Systems receives U.S. government grants for five stem cell projects

Janssen discloses new chemokine CCR2 receptor antagonists

Targeted Genetics enters agreement to acquire Biocontrol

Enrollment complete in ORACLE MS trial of cladribine tablets

EMA approves Cell Therapeutics' pediatric investigation plan for Pixuvri

Phosphasgenics and 3M Pharma join to develop oxycodone pain patch

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...